(Total Views: 342)
Posted On: 06/06/2019 6:23:27 PM
Post# of 156033
From what I gather: If you look at some of these papers pre 2010 here, most are talking about rantes (ccl5).
https://investorshangout.com/post/view?id=5446988
ccl5 interacts with ccr1, ccr3, and ccr5, but ccr5 seems to be the big one with cancer (and, inflammation, etc), so post RP's breast cancer paper, the focus with cancer research was more on ccr5.
example,
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.20306
the CCR5 antagonist TAK779 inhibited CCL5 induced proliferation.
Read More: https://investorshangout.com/post/view?id=544...z5q6puvxi2
https://investorshangout.com/post/view?id=5446988
ccl5 interacts with ccr1, ccr3, and ccr5, but ccr5 seems to be the big one with cancer (and, inflammation, etc), so post RP's breast cancer paper, the focus with cancer research was more on ccr5.
example,
Expression of CCL5 (RANTES) and CCR5 in prostate cancer
https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.20306
the CCR5 antagonist TAK779 inhibited CCL5 induced proliferation.
Read More: https://investorshangout.com/post/view?id=544...z5q6puvxi2
(1)
(0)
